StockData
Trinity Biotech PLC logo

Trinity Biotech PLC (TRIB) stock

TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026Score 1/30
$6.01+0.63 (+11.81%)

Close on Nov 17, 2026Market cap $112.45MP/E –Yield –

Trinity Biotech r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $3.63M, down 20.1% from the year before. Over ten years it grew -3.3% a year on average. The highest annual figure on record is $5.66M in fiscal 2017.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.63M-20.1%
FY2024Dec 31, 2024$4.54M+3.7%
FY2023Dec 31, 2023$4.38M+5.8%
FY2022Dec 31, 2022$4.14M-8.0%
FY2021Dec 31, 2021$4.50M-11.5%
FY2020Dec 31, 2020$5.08M-4.6%
FY2019Dec 31, 2019$5.33M-0.8%
FY2018Dec 31, 2018$5.37M-5.1%
FY2017Dec 31, 2017$5.66M+12.2%
FY2016Dec 31, 2016$5.04M-0.6%
FY2015Dec 31, 2015$5.07M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2018Jun 30, 2018$1.42M–
Q2 FY2017Jun 30, 2017$1.32M–

More Trinity Biotech figures

See a number that looks wrong?